The Relationship Between Behavioral Inhibition and Approach Motivation Systems (BIS/BAS) and Intrinsic Brain Network Connectivity in Adult Cannabis Users

Soc Cogn Affect Neurosci. 2021 May 5:nsab054. doi: 10.1093/scan/nsab054. Online ahead of print. ABSTRACT Dampened behavioral inhibition and overactive behavioral approach motivation systems (i.e., BIS/BAS) are associated with cannabis use disorder (CUD), although the underlying neural mechanisms of these alterations have not yet been examined. The brain’s executive control network Read more…

Partage le savoir

Poisonings by substances of abuse at the Oslo Accident and Emergency Outpatient Clinic 2014-18

Tidsskr Nor Laegeforen. 2021 Apr 29. doi: 10.4045/tidsskr.20.0751. Online ahead of print. ABSTRACT BACKGROUND: Poisonings by substances of abuse are potentially dangerous and indicate risky substance use behaviour. To be prepared to handle patients with poisonings by substances of abuse, we need updated knowledge about the kinds of substances we Read more…

Partage le savoir

Correlates of Self-Reported HIV Testing Among Patients in Specialized Substance Abuse Treatment Centers in South Africa

AIDS Behav. 2021 May 5. doi: 10.1007/s10461-021-03178-z. Online ahead of print. ABSTRACT Substance use is a recognized risk factor for HIV acquisition, transmission and progression in South Africa. Persons who use drugs (PWUD) and access specialist substance abuse treatment centers (SSATCs) are a potentially critical target group for HIV services Read more…

Partage le savoir

The relationship between cannabis and schizophrenia: a genetically informed perspective

Addiction. 2021 May 5. doi: 10.1111/add.15534. Online ahead of print. ABSTRACT BACKGROUND AND AIMS: While epidemiologic studies support a role for heavy, high-potency cannabis use on first episode psychosis, genetic models of causation suggest reverse causal effects of schizophrenia on cannabis use liability. We estimated the genetic relationship between cannabis Read more…

Partage le savoir

Structural correlates of sensorimotor dysfunction in heavy cannabis users

Addict Biol. 2021 May 5:e13032. doi: 10.1111/adb.13032. Online ahead of print. ABSTRACT Sensorimotor dysfunction has been previously reported in persons with cannabis dependence. Such individuals can exhibit increased levels of neurological soft signs (NSS), particularly involving motor coordination and sensorimotor integration. Whether such abnormalities may also apply to non-dependent individuals Read more…

Partage le savoir

A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects

Clin Pharmacol Drug Dev. 2021 May 5. doi: 10.1002/cpdd.950. Online ahead of print. ABSTRACT This pharmacokinetic (PK) drug-interaction trial investigated the effects of repeated dosing of a plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex in the United States and Epidyolex in Europe; 100 mg/mL oral solution) on caffeine Read more…

Partage le savoir

Cannabidiol prevents amphetamine relapse and modulates D1- and D2-receptor levels in mesocorticolimbic brain areas of rats

Eur Neuropsychopharmacol. 2021 May 2;50:23-33. doi: 10.1016/j.euroneuro.2021.04.008. Online ahead of print. ABSTRACT Amphetamine (AMPH) is an addictive psychostimulant highly used worldwide and its consumption is related to neurotoxic effects. Currently, there is no pharmacotherapy approved for treating AMPH or other psychostimulant drug addiction. Different studies have shown promising properties of Read more…

Partage le savoir
error: Content is protected !!